biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Enjoy The Back And Forth Guys

<< Previous

Bullboard Posts

Next >>

Comment by craighenryon Dec 15, 2022 8:38pm

116 Views

Post# 35174814

RE:RE:RE:RE:RE:RE:RE:Enjoy The Back And Forth Guys

JDavenport wrote: Yes, narmac, I mostly have canvassed the dozen or so I've spoken to since this all started.

All want to vote down the deal, but they all know that they don't know enough yet to do it with confidence. That's why I asked the questions this morning in that larger post I made.

If DrDR doesn't have an answer, or has the wrong answer, then thought will have to be given to what actions are possible.

If Bioasis turns out to be in default before a vote can take place, then maybe the TSX would be interested in the fact that a meaningful vote cannot be taken by shareholders, that DrDR has already caused shareholders to lose xB3. Other regulators may also be interested in that.

So, I think we need more information.

jd